Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome

Basit Öğe Kaydı
dc.contributor.authorTurktekin, N.
dc.contributor.authorKarakus, C.
dc.contributor.authorOzyurt, R.
dc.date.accessioned2024-03-13T10:33:38Z
dc.date.available2024-03-13T10:33:38Z
dc.date.issued2022
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractOBJECTIVE: The aim of the study was to compare the effectiveness of calcium gluconate and cabergoline therapy in the prevention of ovarian hyperstimulation syndrome (OHSS). PATIENTS AND METHODS: Eight hundred and forty-five women who underwent GnRH antagonist protocol and at high risk for developing OHSS were divided into two groups. those given cabergoline (n=435) or calcium gluconate (n=410). In cabergoline group, 0.5 mg of cabergoline was administered once daily p.o. starting on the day of ovulation trigger and continued until the following 8 days. In calcium gluconate group, intravenous calcium gluconate was administered daily for four days starting on the day of oocyte pickup (OPU). 10 ml of 10% calcium gluconate solution was dissolved in 200 ml of physiological saline and administered by intravenous route within 40 minutes. Infusion was started within the first 30 minutes following the OPU and continued on the 1st, 2nd and 3rd days after OPU. RESULTS: Mild OHSS was developed in 367 (89%) patients receiving calcium gluconate infusion, while 251 patients (57%) in the cabergoline group developed mild OHSS. The frequency of mild OHSS in the calcium group was significantly higher than the cabergoline group (p<.001). Moderate OHSS was observed in 32 people (7.8%) in the calcium gluconate group, while it was observed in 184 people in the cabergoline group (42.3%). Calcium gluconate infusion significantly reduced the development of moderate OHSS compared to cabergoline therapy (p<.001). Severe OHSS developed in 11 patients (2.7%) in the calcium gluconate group, while severe OHSS did not develop in those given cabergoline (0%. p<.001). Clinical pregnancy, live birth and abortion rates were similar in the two groups. When logistic regression analysis was performed. a significant correlation was found between age, BMI. AMH, the number of antral follicle count, OHSS history, paracentesis. progesterone on the day of hCG. 2 PN zygotes, and HbA1c levels and the development of OHSS. No correlation was found between the use of metformin or cetrotide and the development of OHSS. CONCLUSIONS: Calcium gluconate treatment is not effective in the prevention of OHSS.en_US
dc.identifier.endpage1254en_US
dc.identifier.issn1128-3602
dc.identifier.issue4en_US
dc.identifier.pmid35253181en_US
dc.identifier.scopus2-s2.0-85125871963
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1248en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12662/4072
dc.identifier.volume26en_US
dc.identifier.wosWOS:000763332500025
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical And Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOHSSen_US
dc.subjectCalcium gluconateen_US
dc.subjectCabergolineen_US
dc.subjectPCOen_US
dc.titleCalcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu